The following video is part of our "Motley Fool Conversations" series, in which health-care editor/analyst David Williamson discusses topics across the investing world.
In today's edition, David discusses whether Chelsea Therapeutics is a bad news buy. Shares have collapsed more than 60% year to date; its Neurogenic Orthostatic Hypotension (NOH) drug Nothera received a rejection in March. After meeting with the FDA, it looks like the FDA's complaints are more complicated for Chelsea than originally anticipated. Does additional uncertainty mean it's time to buy? Watch and find out.
Health-care investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health-care company that he believes is poised for monster returns. To uncover this top pick today, enjoy the special free report "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.
At the time thisarticle was published David Williamsonhas no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter servicesfree for 30 days. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.